In one such therapy, the administration of low-dose irinotecan and TRAIL upregulated DR5 expression in TRAIL-resistant HT-29 CRC cells, with the subsequent activation of caspases [72]. The gene discussed is TNFSF10; the disease is colorectal carcinoma.